Public health-friendly options for protecting pharmaceutical registration data

International Journal of Intellectual Property Management

Volumn 1, Issue 1-2, 2006, Pages 113-130

  Weissman, Robert ^a  

^a HARVARD LAW SCHOOL   (United States)

Author keywords

Compulsory licensing; Cost sharing; Data exclusivity; Data protection; Marketing approval data; Misappropriation; Registration data; TRIPS; WTO

Indexed keywords

EID: 33847672775     PISSN: 14789647     EISSN: 14789655     Source Type: Journal    
DOI: 10.1504/IJIPM.2006.011025     Document Type: Article

References (11)

1. Avecia and Mareva Piscines Et Filtration's (2002) In the Matter of the Arbitration Between Avecia, Inc. and Mareva Piscines Et Filtration's, S.A., Arbitrator's Decision and Award, Case No. 23 171 00170 99, Before the American Arbitration Association, August 15.
2. Cheminova and Griffin (2001) In the Matter of the Arbitration Between Cheminova A/S and Griffin L.L.C., Arbitrator's Decision and Award, Docket No.: 23 171 00020 99, Before the American Arbitration Association, June 29.
3. Ciba-Geigy and Drexel Chemical (1994) In the Matter of the Arbitration Between Ciba-Geigy Corporation and Drexel Chemical Corporation, Arbitrator's Decision and Award, Docket No.: 16 171 00321 92G, Before the American Arbitration Association, August 15.
4. Correa, C.M. (2002) Protection of Data Submitted for the Registration of Pharmaceuticals: Implementing the Standards of the Trips Agreement, South Centre, Geneva, Switzerland.
5. Dowelanco and Albaugh (1998) In the matter of the Arbitration between Dowelanco and The Trifluralin Data Development Consortium, and Albaugh, Inc., Arbitrator's Decision and Award, FIFRA Case No. 52 Y 171 00100 95, Before the American Arbitration Association, June 1.
6. Enviro-Chem and Lilly (1999) In the Matter of the Arbitration Between Enviro-Chem, Inc. and Lilly Industries, Inc. Arbitrator's Decision and Award, Docket No.: 23-171-00003-97 (formerly 16-171-00018-97P), Before the American Arbitration Association, Award Issued June 4, 1999, Public Version Released July 22.
7. Gorlin, J. (2000) Encouragement of new Clinical Drug Development: The Role of Data Exclusivity, IFPMA, Geneva.
8. Indian Institute of Foreign Trade (2003) Article 39.3 of the TRIPS Agreement: Its Genesis and the Present Context, New Delhi.
9. International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (2005) A Review of Existing Data Exclusivity Legislation in Selected Countries, Fifth Revised Version, April.
10. Microgen and Lonza (2000) In the Matter of the Arbitration Between Microgen, Inc. and Lonza, Inc., Arbitrator's Decision and Award, Docket No.: 23-171-00003-96, Before the American Arbitration Association, May 10.
11. Proem and Grapetek (1999) In the Matter of the Arbitration Between Proem, Ltda, Productos Quimicos Y Alimenticios Asku S.A. (OSKU), Quimetal Industrial S.A. (Quimetal), Chilean Exporters Association and Grapetek (Pty) Ltd., Arbitrator's Decision and Award, Docket No.: 23 171 00027 98, Before the American Arbitration Association, June 17.